Host Cell Factor Targeting for Influenza Antiviral Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiviral drugs for influenza virus infection face challenges such as limited targets, rapid viral resistance, and toxicity issues when targeting host cell factors, necessitating the development of new strategies to combat influenza virus replication.
Innovation Solution
Compounds like nucleic acid compounds (e.g., siRNAs) and small molecules that target human host cell factors involved in influenza virus replication, modulating their expression or activity to inhibit viral replication, thereby reducing the emergence of resistant strains and expanding antiviral intervention targets.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antiviral drugs target viral proteins, then the virus replication is inhibited, but viral resistance develops rapidly and the number of targets is limited
Solution Approach 1:
Instead of targeting viral proteins directly, the patent inverts the approach by targeting host cell factors that are essential for viral replication. This inversion shifts the battlefield from the viral side to the host side, making it difficult for the virus to develop resistance since the host factors are not part of the viral genome and cannot be mutated to escape inhibition.
Solution Approach 2:
The patent identifies host cell factors that perform multiple functions, including both viral replication and essential host cellular processes. By targeting these multi-functional factors, the patent achieves broad antiviral efficacy across different influenza strains while maintaining host cell viability through selective inhibition strategies.
2Adaptability or versatility
If antiviral drugs target host cell factors, then the number of intervention targets is expanded, but toxicity to the host increases
Solution Approach 1:
The patent applies local quality by selectively targeting specific host cell factors that are locally essential for viral replication rather than broadly inhibiting all host functions. This selective targeting approach expands the number of viable antiviral targets while minimizing general toxicity to host cells through precise molecular intervention at specific cellular locations and functions.
Solution Approach 2:
The patent utilizes parameter changes by modifying the pharmacological properties of compounds to achieve selective inhibition of host factors involved in viral replication. Through careful adjustment of compound structure, binding affinity, and cellular penetration parameters, the patent achieves effective antiviral activity while maintaining host cell safety margins.
3Reliability
If existing antiviral drugs are used, then influenza infection is treated, but resistance has developed in recent seasons
Solution Approach 1:
The patent inverts the traditional antiviral strategy by targeting host cell factors instead of viral proteins. This inversion creates a fundamental shift in the treatment approach that is not susceptible to viral resistance mechanisms, as the host factors cannot be mutated to escape inhibition. This approach maintains treatment effectiveness regardless of viral genetic composition changes.
Data Source
AI summary
This application relates to the modulation of host cell factors required for influenza virus replication. The application relates to compounds, including nucleic acid compounds (such as, e.g., small interfering RNAs (siRNAs)) and small molecules, that target human host cell factors involved in influenza virus replication, and the use of such compounds for modulating influenza virus replication and as antiviral agents. The application also relates to methods of treating an influenza virus infection and methods of treating or preventing a symptom or disease associated with influenza virus infection, comprising administering to a subject a composition comprising a compound, such as a nucleic acid compound (e.g., an siRNA) or small molecule, that targets a human host cell factor involved in influenza virus replication.